Granzymes: Silent Executors of Immune Defense and Their Expanding Clinical Relevance

Few molecular players in immunology carry the dual weight of precision and potency quite like granzymes. These serine proteases, stored within the cytotoxic granules of CD8⁺ T lymphocytes and natural killer (NK) cells, have been at the center of cytotoxicity research for over three decades. Yet despite their long history, granzymes continue to generate significant scientific excitement — particularly as the era of cancer immunotherapy, single-cell transcriptomics, and immune biomarker discovery redefines what we thought we knew about these enzymes. Understanding granzyme biology has never been more critical for researchers aiming to dissect immune effector mechanisms or develop next-generation immunotherapies. For laboratories investigating granzyme-mediated pathways, having access to reliable quantitative detection tools is essential. Our company supports this research with a comprehensive portfolio of ELISA kits, matched antibody pairs, and custom assay development services tailored to granzyme quantification — from high-sensitivity Granzyme B detection for biomarker studies to multiplex panels that simultaneously profile multiple granzyme family members in precious clinical samples. By combining deep scientific knowledge with specialized reagent solutions, we help immunology and oncology researchers move from hypothesis to actionable data with confidence.

Browse More Granzymes Products

Figure 1. Classical granzyme B (GrB)/perforin-mediated apoptosis pathway. (Source: Boivin WA, et al. 2009)

The Granzyme Family

In humans, five granzymes have been characterized: Granzyme A (GzmA), Granzyme B (GzmB), Granzyme H (GzmH), Granzyme K (GzmK), and Granzyme M (GzmM). Together, they form a structurally related but functionally diverse family of chymotrypsin-like serine endoproteases. All granzymes are synthesized as inactive precursors (zymogens), processed by cathepsin C (dipeptidyl peptidase I) to their mature active forms, and stored in electron-dense lytic granules alongside the pore-forming protein perforin. Upon target cell recognition, these granules are polarized and exocytosed at the immunological synapse, and granzymes gain access to the target cell cytoplasm through perforin-dependent and, as more recent work has demonstrated, perforin-independent pathways.

Each granzyme member has a distinct cleavage specificity that determines its downstream substrates. GzmA cleaves after basic residues (Arg or Lys), whereas GzmB has an unusual preference for aspartate residues — a feature shared with caspases. GzmK, like GzmA, is a tryptase, but it acts on different substrates and through mechanisms distinct from GzmA. GzmM preferentially cleaves after methionine or leucine residues. GzmH, the least studied, has chymotryptic activity targeting viral proteins. This substrate diversity means that, collectively, granzymes can engage multiple death pathways within the same target cell, substantially reducing the odds of escape.

Granzyme B: The Most Studied Member and Emerging Therapeutic Relevance

Of all the granzymes, GzmB has received the most scientific and clinical attention, and for good reason. Its ability to directly activate caspases — particularly caspase-3 — provides a fast, decisive route to apoptosis in target cells. GzmB cleaves the BH3-only protein Bid, releasing cytochrome c from mitochondria and amplifying the death signal through the intrinsic apoptotic pathway. Simultaneously, it targets structural proteins such as lamin B and PARP, contributing to nuclear collapse.

What has fundamentally shifted the field in recent years is the recognition that GzmB is not exclusive to cytotoxic lymphocytes. Multiple studies have now demonstrated its expression in regulatory T cells, mast cells, basophils, plasmacytoid dendritic cells, and even certain tumor cells themselves. This expanded cellular expression changes the paradigm: rather than simply being a weapon of cytotoxic immunity, GzmB appears to be a multifunctional protease with roles in inflammation, extracellular matrix remodeling, and tissue pathology. A 2024 research publication specifically emphasized the importance of "perforin-independent" GzmB activities, linking extracellular GzmB to fibrosis, skin disorders including keloids, and neurodegenerative inflammation. Elevated extracellular GzmB has been detected in the serum and tissues of patients with autoimmune diseases such as rheumatoid arthritis, lupus, and scleroderma, making it a compelling biomarker candidate. In the oncology space, a notable 2022 investigation described a fluorogenic probe capable of detecting GzmB activity directly in tumor biopsies, positioning intratumoral GzmB as a predictive marker for response to immune checkpoint inhibitor therapy.

Beyond Granzyme B: The Underappreciated Members

While GzmB dominates the literature, the other family members are attracting growing interest as the field recognizes that immune killing is not a one-enzyme show. GzmA operates through a caspase-independent, single-stranded DNA nicking mechanism involving the SET complex, a nuclear substrate that becomes a target for GzmA-mediated disassembly. This pathway is particularly relevant in the context of viral infections and antitumor immunity where caspase activation may be suppressed or evaded by the target. GzmA has also been linked to inflammatory cytokine production; its extracellular activity can cleave substrates such as pro-IL-18, contributing to broader inflammatory programs beyond simple cytolysis.

GzmK shares tryptase activity with GzmA but demonstrates distinct substrate preferences, including vitronectin and fibronectin in the extracellular space, as well as nuclear proteins within target cells. It has been proposed to serve as a backup to GzmA when the primary pathway is compromised. Meanwhile, GzmM is most highly expressed in NK cells and has been shown to contribute to rapid cytolysis of tumor cells through the cleavage of survivin and HSP70, proteins that are frequently upregulated in cancers as survival mechanisms. The fact that tumors may rely on survivin for protection against cell death makes GzmM a particularly interesting candidate in the context of overcoming apoptosis resistance. GzmH, expressed predominantly in NK cells and cytomegalovirus (CMV)-specific T cells, has demonstrated activity against adenoviral DNA-binding protein, implicating it in antiviral immune defense. These less-characterized granzymes underscore the redundancy and adaptability built into cytotoxic immunity.

Granzymes in the Context of Cancer Immunotherapy

The explosion of interest in immune checkpoint inhibitor (ICI) therapy — targeting pathways such as programmed cell death protein 1 (PD-1), its ligand PD-L1, and cytotoxic T-lymphocyte antigen 4 (CTLA-4) — has renewed the spotlight on granzyme-mediated killing as the downstream effector mechanism that truly matters for tumor clearance. A patient whose PD-1 pathway is successfully blocked will only benefit if the unleashed CD8⁺ T cells are capable of effective granzyme-mediated cytolysis. Transcriptomic studies using single-cell RNA sequencing have consistently shown that GzmB and GzmK expression in tumor-infiltrating lymphocytes (TILs) correlates strongly with clinical response to ICIs across multiple tumor types, including non-small cell lung cancer, melanoma, and urothelial carcinoma.

Beyond serving as a biomarker, granzymes are also being explored as active therapeutic tools. The concept of granzyme-armed immunotoxins — fusion proteins linking a targeting antibody fragment to a recombinant granzyme — has been investigated as a strategy to deliver cytotoxic payloads directly to antigen-expressing tumor cells. Separately, the field of chimeric antigen receptor (CAR) T-cell engineering has begun examining whether augmenting intracellular granzyme levels or granule exocytosis efficiency can enhance CAR T-cell potency, particularly against solid tumors where immunosuppressive conditions often impair CTL function. These developments position granzymes not merely as passive indicators of immune activity, but as active molecular levers that can potentially be engineered for greater therapeutic effect.

Figure 2. The function and mechanism of granzyme B in antitumor immunity. (Source: Tong X, et al. 2025)

Granzymes in Autoimmunity, Aging, and Non-Cytotoxic Pathology

One of the most striking recent reappraisals of granzyme biology involves their roles outside of conventional cytotoxic immunity. Accumulating evidence points to granzymes — particularly GzmB — as significant contributors to chronic inflammatory and fibrotic conditions. In aged skin and sun-damaged tissue, extracellular GzmB accumulates due to a relative deficiency of its natural inhibitor, and this enzymatic activity cleaves structural extracellular matrix components such as collagen and fibronectin, impairing wound healing and promoting fibrotic remodeling. A 2025 editorial review summarized emerging work linking granzyme-mediated extracellular proteolysis to the pathogenesis of conditions ranging from aortic aneurysm and atherosclerosis to neuroinflammation and age-related tissue deterioration. This "dark side" of granzyme biology — where the same enzymes that protect against cancer and infection become destructive in the context of dysregulated chronic inflammation — is now a major focus of research and a compelling rationale for developing selective granzyme inhibitors as therapeutics.

In autoimmune disease, the picture is complex. On one hand, CTL-mediated granzyme release contributes to target tissue destruction in diseases such as type 1 diabetes (islet cell killing), multiple sclerosis (oligodendrocyte damage), and inflammatory myopathies. On the other hand, granzyme-expressing regulatory T cells may use these enzymes to suppress excessive immune responses by killing activated effector cells, suggesting a bidirectional regulatory function. This duality makes it difficult to simply block granzymes globally and demands a nuanced, context-specific therapeutic approach.